Enhance Biotech has received clearance from the FDA to proceed with Phase I clinical trials for its propriety selective delta agonist, DPI-221, for urge and mixed urinary incontinence (UI). This is a novel mechanism for the potential treatment of UI. The trial for DPI-221 is planned to begin in early 2006.
UI is a common illness, particularly in the growing elderly population. It is defined as the uncontrollable loss of urine from the bladder and is the primary cause of institutionalization of the elderly. The syndrome is comprised primarily of three subtypes: urge incontinence, stress incontinence and mixed incontinence. The target condition for DPI-221 is urge and mixed incontinence, in which the patient cannot control the emptying of the bladder appropriately after the recognition of the need to urinate.